A large study of 20,000 hospitalised Coronavirus affected patients who received transfusions of blood plasma from recovered COVID-19 patients found the treatment was safe.
The study published in the Journal Mayo Clinic Proceedings on Thursday, assessed the seven days following transfusion for hospitalised COVID-19 patients between April 3 and June 11 who were deemed at risk of progressing to a critical condition.
Nearly 40% of the COVID-19 positive patients were women; 20% African Americans; 35% Hispanic and 5% Asian, the researchers mentioned.
Seven days mortality rates declined to 8.6% compared to 12% in a previous safety study of the first 5,000 transfused COVID positive patients, the researchers said.
They also said, Serious adverse events continued to be less than one percent.
Michael Joyner, principal investifator at Mayo Clinic United States, and lead author of the research article said, Our efforts to understand convalascent plasma continue. We're optimistic but must remain objective as we assess incrasing amount of data.
The study reveals a decline in mortality which appears contemporary with the more rapid availability of blood plasma for use, according to the scientists.
However, scientists caution that this alone does not provide any evidence on effectiveness of convalascent plasma for treating Coronavirus.
At this time, convalascent blood plasma therapy is the only antibody based therapy for Coronavirus, they stated.